Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Moodys
McKinsey
Boehringer Ingelheim
Baxter
Express Scripts
Colorcon

Last Updated: December 8, 2019

DrugPatentWatch Database Preview

Fosamprenavir calcium - Generic Drug Details

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What are the generic sources for fosamprenavir calcium and what is the scope of freedom to operate?

Fosamprenavir calcium is the generic ingredient in two branded drugs marketed by Viiv Hlthcare and Mylan, and is included in three NDAs. There is one patent protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Fosamprenavir calcium has fifty-seven patent family members in forty-six countries.

There are four drug master file entries for fosamprenavir calcium. Three suppliers are listed for this compound. There is one tentative approval for this compound.

Recent Clinical Trials for fosamprenavir calcium

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Fundação de Amparo à Pesquisa do Estado de São PauloPhase 4
Federal University of São PauloPhase 4
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)Phase 2/Phase 3

See all fosamprenavir calcium clinical trials

Recent Litigation for fosamprenavir calcium

Identify potential future generic entrants

District Court Litigation
Case NameDate
ViiV Healthcare Company v. Lupin Limited2017-03-23

See all fosamprenavir calcium litigation

PTAB Litigation
PetitionerDate
Lupin Limited2016-02-03
Lupin Limited2014-12-10
Ranbaxy Laboratories Ltd.2012-10-18

See all fosamprenavir calcium litigation

Generic filers with tentative approvals for FOSAMPRENAVIR CALCIUM
Applicant Application No. Strength Dosage Form
  Start Trial  Start Trial700MGTABLET;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Synonyms for fosamprenavir calcium
((3S)Oxolan-3-yloxy)-N-((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-1-benzyl-2-(phosphonooxy)propyl)carboxamide calcium salt
(3S)-Tetrahydro-3-furyl ((alphaS)-alpha-((1R)-1-hydroxy-2-(N(sup 1)-isobutylsulfanilamido)ethyl)phenethyl)carbamate, calcium phosphate (ester) (1:1)
226700-81-8
AB1004608
AC1L2ZCL
AKOS015950832
Amprenavir phosphate calcium
AN-16772
AX8246818
C25H34CaN3O9PS
calcium [(1R,2S)-1-[[(4-aminophenyl)sulfonyl-isobutyl-amino]methyl]-3-phenyl-2-[[(3S)-tetrahydrofuran-3-yl]oxycarbonylamino]propyl] phosphate
calcium [(2R,3S)-1-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-3-[[(3S)-oxolan-3-yl]oxycarbonylamino]-4-phenylbutan-2-yl] phosphate
Calcium [(3S)-oxolan-3-yl] N-[(2S,3R)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-1-phenyl-3-phosphonatooxy-butan-2-yl]carbamate
Carbamic acid, ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-1-(phenylmethyl)-2-(phosphonooxy)propyl)-, C-((3S)-tetrahydro-3-furanyl) ester, calcium salt
Carbamic acid, ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-1-(phenylmethyl)-2-(phosphonooxy)propyl)-, C-((3S)-tetrahydro-3-furanyl) ester, calcium salt (1:1)
CAS-226700-81-8
CHEMBL1200734
CS-1411
D03835
DSSTox_CID_26777
DSSTox_GSID_46777
DSSTox_RID_81896
DTXSID0046777
Fosamprenavir (Calcium Salt)
Fosamprenavir calcium (USAN)
Fosamprenavir calcium [USAN]
Fosamprenavir calcium, >=98% (HPLC)
FT-0668861
GW 433908G
GW-433908
GW-433908G
GW433908G
HY-17431
ID1GU2627N
Lexiva
Lexiva (TN)
LS-186584
MLS006012033
MolPort-021-783-037
NCGC00168771-01
PMDQGYMGQKTCSX-HQROKSDRSA-L
SCHEMBL1649283
SMR004703563
ST2419393
Telzir (TN)
Tox21_112632
UNII-ID1GU2627N
Z4451
Paragraph IV (Patent) Challenges for FOSAMPRENAVIR CALCIUM
Tradename Dosage Ingredient NDA Submissiondate
LEXIVA TABLET;ORAL fosamprenavir calcium 021548 2012-01-18

US Patents and Regulatory Information for fosamprenavir calcium

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mylan FOSAMPRENAVIR CALCIUM fosamprenavir calcium TABLET;ORAL 204060-001 Apr 15, 2016 AB RX No No   Start Trial   Start Trial   Start Trial
Viiv Hlthcare LEXIVA fosamprenavir calcium TABLET;ORAL 021548-001 Oct 20, 2003 AB RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Viiv Hlthcare LEXIVA fosamprenavir calcium SUSPENSION;ORAL 022116-001 Jun 14, 2007 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for fosamprenavir calcium

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Viiv Hlthcare LEXIVA fosamprenavir calcium SUSPENSION;ORAL 022116-001 Jun 14, 2007   Start Trial   Start Trial
Viiv Hlthcare LEXIVA fosamprenavir calcium TABLET;ORAL 021548-001 Oct 20, 2003   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for fosamprenavir calcium

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0933372 13/2008 Austria   Start Trial PRODUCT NAME: FOSAMPRENAVIR ALS FOSAMPRENAVIR-CALCIUM; REGISTRATION NO/DATE: EU/1/04/282/001 - EU/1/04/282/002 (MITTEILUNG VOM 14.07.2004) 20040713
0933372 PA2008006,C0933372 Lithuania   Start Trial PRODUCT NAME: FOSAMPRENAVIR CALCIUM; REGISTRATION NO/DATE: EU/1/04/282/001-002 20040712
0933372 08C0015 France   Start Trial PRODUCT NAME: FOSAMPRENAVIR CALCIQUE; REG. NO/DATE: EU/1/07/282/001-002 20040712
0933372 PA2008006 Lithuania   Start Trial PRODUCT NAME: FOSAMPRENAVIR CALCIUM; REGISTRATION NO/DATE: EU/1/04/282/001-002 20040712
0933372 SPC/GB08/018 United Kingdom   Start Trial PRODUCT NAME: FOSAMPRENAVIR CALCIUM: ((1S,2R)-3-(((4-AMINOPHENYL)SULFONYL)(2-METHYLPROPYL)AMINO)-1-(PHENYLMETHYL)-2(PHOSPHONOOXY)PROPYL)-CARBABAMIC ACID C-((3S)-TETRAHYDRO-3-FURANYL) ESTER CALCIUM SALT; REGISTERED: UK EU/1/04/282/001 20040712; UK EU/1/04/282/002 20040712
0933372 C00933372/01 Switzerland   Start Trial PRODUCT NAME: FOSAMPRENAVIR; REGISTRATION NUMBER/DATE: SWISSMEDIC 56706 17.03.2005
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Moodys
Merck
Baxter
AstraZeneca
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.